About VISEN Pharmaceuticals
VISEN Pharmaceuticals is a company based in Shanghai (China) founded in 2018.. VISEN Pharmaceuticals has raised $150 million across 1 funding round from investors including Ascendis Pharma, Orbimed and HBM Healthcare Investments. The company has 3 employees as of December 31, 2022. VISEN Pharmaceuticals operates in a competitive market with competitors including Neurocrine, Ironwood Pharma, Crinetics, Zucara Therapeutics and MBX Biosciences, among others.
- Headquarter Shanghai, China
- Employees 3 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Visen
-
Annual Revenue
-
Net Profit
$-25.44 M (USD)28.35as on Dec 31, 2024
-
EBITDA
$-24.08 M (USD)-29.55as on Dec 31, 2024
-
Total Equity Funding
$150 M (USD)
in 1 rounds
-
Latest Funding Round
$150 M (USD), Series B
Jan 08, 2021
-
Investors
Ascendis Pharma
& 9 more
-
Employee Count
3
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Leadership Team
2 people
Human Resources and Administration
1 people
Sales and Marketing
1 people
Unlock access to complete
Funding Insights of VISEN Pharmaceuticals
VISEN Pharmaceuticals has successfully raised a total of $150M through 1 strategic funding round. The most recent funding activity was a Series B round of $150 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series B — $150.0M
-
First Round
First Round
(08 Jan 2021)
- Investors Count 10
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2021 | Amount | Series B - VISEN Pharmaceuticals | Valuation | Sequoia Capital |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in VISEN Pharmaceuticals
VISEN Pharmaceuticals has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Ascendis Pharma, Orbimed and HBM Healthcare Investments. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Life sciences focused VC firm funding companies in the US and Europe
|
Founded Year | Domain | Location | |
|
A venture capital firm focused on life sciences innovation.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by VISEN Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - VISEN Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Visen Pharmaceuticals Comparisons
Competitors of VISEN Pharmaceuticals
VISEN Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Neurocrine, Ironwood Pharma, Crinetics, Zucara Therapeutics and MBX Biosciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| domain | founded_year | HQ Location |
Therapeutics for gastrointestinal disorders, including linaclotide, are developed.
|
|
| domain | founded_year | HQ Location |
Developer of therapies for the treatment of endocrine-related diseases and cancers
|
|
| domain | founded_year | HQ Location |
Developing a long-term therapeutic approach to prevent hypoglycemia in patients with diabetes
|
|
| domain | founded_year | HQ Location |
Drugs for rare endocrine diseases are developed and advanced.
|
|
| domain | founded_year | HQ Location |
Peptide-targeted radiopharmaceuticals for cancer treatment are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Visen Pharmaceuticals
Frequently Asked Questions about VISEN Pharmaceuticals
When was VISEN Pharmaceuticals founded?
VISEN Pharmaceuticals was founded in 2018 and raised its 1st funding round 3 years after it was founded.
Where is VISEN Pharmaceuticals located?
VISEN Pharmaceuticals is headquartered in Shanghai, China.
Who is the current CEO of VISEN Pharmaceuticals?
Pony Lu is the current CEO of VISEN Pharmaceuticals.
Is VISEN Pharmaceuticals a funded company?
VISEN Pharmaceuticals is a funded company, having raised a total of $150M across 1 funding round to date. The company's 1st funding round was a Series B of $150M, raised on Jan 08, 2021.
How many employees does VISEN Pharmaceuticals have?
As of Dec 31, 2022, the latest employee count at VISEN Pharmaceuticals is 3.
What does VISEN Pharmaceuticals do?
VISEN Pharmaceuticals was founded in 2018 and is headquartered in Shanghai, China. Operations focus on the biotechnology sector, where therapeutics for endocrine-related diseases are developed through the proprietary TransCon platform for transient conjugation. Key products include TransCon hGH for pediatric growth hormone deficiency, TransCon PTH for hypoparathyroidism, and TransCon CNP for achondroplasia, addressing deficiencies in hormone secretion or gland function.
Who are the top competitors of VISEN Pharmaceuticals?
VISEN Pharmaceuticals's top competitors include Ironwood Pharma, Crinetics and Neurocrine.
Who are VISEN Pharmaceuticals's investors?
VISEN Pharmaceuticals has 10 investors. Key investors include Ascendis Pharma, Orbimed, HBM Healthcare Investments, Sherpa Venture Capital, and Pivotal bioVenture Partners.